Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer - Related Studies

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

This study is ongoing, but not recruiting participants.

Study NCT00031837. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer-Related Problem/Condition
		Pancreatic Cancer

2	Additional conditions recognized in this trial
		Pancreatic Neoplasms

3	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Neoplasms
		Neoplasms by Site
		Pancreatic Diseases

4	Interventions listed in this trial
		dalteparin
		gemcitabine hydrochloride
		quality-of-life assessment

5	Additional drug interventions recognized in this trial
		Gemcitabine

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Anticoagulants
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Cardiovascular Agents
		Enzyme Inhibitors
		Fibrin Modulating Agents
		Fibrinolytic Agents
		Hematologic Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		University of Rochester
		National Cancer Institute (NCI)